Researchers track Real-Life use of breast cancer drug
NCT ID NCT04671615
Summary
This study aimed to understand how the breast cancer drug palbociclib is actually used in everyday medical practice in Israel. It observed 559 adult patients whose breast cancer had spread and who were already prescribed this drug as part of their standard care. The goal was to collect information on treatment patterns, how long patients stayed on the drug, and their health outcomes over about 3.5 years.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Pfizer Pharmaceuticals Israel Ltd.
Herzliya Pituah, 4672509, Israel
Conditions
Explore the condition pages connected to this study.